Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 29, 2018

View Archived Issues

MedImmune initiates phase I study of MEDI-6570

89Bio launches to develop drug for NASH

France becomes first country to market baclofen preparation to reduce alcohol consumption

Boehringer Ingelheim initiates phase I study of BI-730460

Uniparental mice give insights into ESC imprinting

Dual ICOS/CD28 antagonist demonstrates efficacy in models of autoimmune disease

Single locus near SIM1 gene significantly associated with risk of erectile dysfunction

OT-1096, a novel immunoactivating molecule that shows efficacy in xenograft models of TNBC

Phase I U.S. data presented for KN-035 in patients with advanced solid tumors

Pfizer and Novartis collaborate to study NASH therapy combinations

ASP-5094 safe and well tolerated in patients with rheumatoid arthritis on methotrexate

Griffithsin intravaginal gel well tolerated in first-in-human trial

Opthea reports promising 12-week data from phase Ib study of OPT-302 in DME

Novo Nordisk reports PIONEER 8 topline results with oral semaglutide in type 2 diabetes

Phase II data presented for SEL-212 in symptomatic gout patients

Novartis reports year 2 data from brolucizumab phase III trials in wet AMD

Genentech presents data on faricimab and ranibizumab PDS in wet AMD

Aduro initiates phase I study of ADU-1604 in metastatic melanoma

New phase I trial evaluates TAK-981 in metastatic solid tumors or lymphomas

Qrumpharma develops inhaled agent for nontuberculous mycobacterial infections

Innovate demonstrates preclinical proof of concept for larazotide in NASH mouse model

New phase Ib/IIa study explores use of AG-019 for treatment of early-onset type 1 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...